Download PDF
Thromb Haemost 2020; 120(03): 449-456
DOI: 10.1055/s-0039-3402758
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study

Bogumił Ramotowski
1   Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland
,
Paul A. Gurbel
2   Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, Virginia, United States
,
Udaya Tantry
3   Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, LifebridgeHealth, Baltimore, Maryland, United States
,
Jan S. Bracha
1   Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland
,
Marta Karaźniewicz-Łada
4   Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznan, Poland
,
Zbigniew Lewandowski
5   Department of Epidemiology and Biostatistics, Medical University of Warsaw, Warsaw, Poland
,
Andrzej Budaj
1   Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland
› Author Affiliations Funding This study was supported by a grant from the Centre of Postgraduate Medical Education (no. 501–1-10–14–16/17).
Further Information

Publication History

30 June 2019

15 November 2019

Publication Date:
15 January 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Background Cigarette smoking is associated with enhanced clopidogrel effect and platelet inhibition. However, the effect of smoking cessation on clopidogrel pharmacokinetics (PK) and pharmacodynamics (PD) is unknown. We aimed to determine the effect of smoking cessation, confirmed by cotinine measurement, on clopidogrel PK and PD after percutaneous coronary intervention (PCI).

Methods and Results Following successful PCI, patients treated with 75 mg/day clopidogrel who reported smoking ≥10 cigarettes/day with NicAlert urine cotinine level 6 were enrolled. Clopidogrel and its metabolite concentrations, VerifyNow P2Y12 reaction units (PRUs), and NicAlert levels were measured in the study group before and at 30 days after smoking cessation and in a control group. CYP1A2 and CYP2C19 genotypes were determined. At 30-day visit (n = 87), 45 patients continued smoking, whereas 42 patients stopped smoking. Baseline PRUs were similar between groups. At 30 days, the smoking cessation group had higher PRUs (150.5 ± 68.6 vs. 118.4 ± 65.9, p = 0.03), greater absolute PRU change (27.7 ± 39.8 vs. −12.9 ± 55.4, p = 0.0002), greater change of PRUs adjusted for baseline platelet reactivity (38.6 ± 10.0, p < 0.01), greater risk of high platelet reactivity (HPR) (odds ratio: 10.14 [1.52–67.5], p = 0.017), and a trend towards decreased H3 clopidogrel metabolite levels (−3.41 ng/mL [−11.00 to 0.54 ng/mL], p = 0.072). CYP2C19 LoF carriers who stopped smoking had the highest PRUs, whereas those with the wild type who continued smoking had the lowest PRUs (p < 0.008).

Conclusion Smoking cessation in clopidogrel-treated patients after PCI is associated with increased platelet reactivity and greater risk of HPR. Alternative P2Y12 inhibitors may be considered in selected patients who stop smoking after PCI.

Keywords

clopidogrel - platelet reactivity - smoking

Note

The work was performed at the Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland.


 

  • References

  • 1 Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis 2009; 205 (01) 23-32
    CrossrefPubMedGoogle Scholar
  • 2 Gurbel PA, Baker BA, Bailey WL, Bliden KP, Tantry US. Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors. Thromb Haemost 2014; 111 (06) 1187-1190
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Swiger KJ, Yousuf O, Bliden KP, Tantry US, Gurbel PA. Cigarette smoking and clopidogrel interaction. Curr Cardiol Rep 2013; 15 (05) 361
    CrossrefPubMedGoogle Scholar
  • 4 Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012; 307 (23) 2495-2496
    PubMedGoogle Scholar
  • 5 Gurbel PA, Bliden KP, Logan DK. , et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013; 62 (06) 505-512
    CrossrefPubMedGoogle Scholar
  • 6 Kazui M, Nishiya Y, Ishizuka T. , et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38 (01) 92-99
    CrossrefPubMedGoogle Scholar
  • 7 Park KW, Park JJ, Jeon KH. , et al. Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 2011; 31 (03) 665-671
    CrossrefPubMedGoogle Scholar
  • 8 Patti G, Polacco M, Taurino E, Gaudio C, Greco C. Effects of cigarette smoking on platelet reactivity during P2Y12 inhibition in patients with myocardial infarction undergoing drug-eluting stent implantation: results from the prospective cigarette smoking on platelet reactivity (COPTER) study. J Thromb Thrombolysis 2016; 41 (04) 648-653
    CrossrefPubMedGoogle Scholar
  • 9 Park KW, Kang SH, Kang J. , et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by Verify Now assay: additional evidence for the concept of ‘smokers’ paradox'. Heart 2012; 98 (13) 1000-1006
    PubMedGoogle Scholar
  • 10 Park MB, Kim CB, Nam EW, Hong KS. Does South Korea have hidden female smokers: discrepancies in smoking rates between self-reports and urinary cotinine level. BMC Womens Health 2014; 14: 156
    CrossrefPubMedGoogle Scholar
  • 11 Price MJ, Berger PB, Teirstein PS. , et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305 (11) 1097-1105
    CrossrefPubMedGoogle Scholar
  • 12 Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107 (23) 2908-2913
    CrossrefPubMedGoogle Scholar
  • 13 Jeong YH, Bliden KP, Antonino MJ, Park KS, Tantry US, Gurbel PA. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am Heart J 2012; 164 (01) 35-42
    CrossrefPubMedGoogle Scholar
  • 14 Tantry US, Bonello L, Aradi D. , et al; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62 (24) 2261-2273
    CrossrefPubMedGoogle Scholar
  • 15 Karaźniewicz-Łada M, Danielak D, Teżyk A, Zaba C, Tuffal G, Główka F. HPLC-MS/MS method for the simultaneous determination of clopidogrel, its carboxylic acid metabolite and derivatized isomers of thiol metabolite in clinical samples. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 911: 105-112
    CrossrefPubMedGoogle Scholar
  • 16 Karaźniewicz-Łada M, Danielak D, Burchardt P. , et al. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet 2014; 53 (02) 155-164
    CrossrefPubMedGoogle Scholar
  • 17 Giusti B, Gori AM, Marcucci R. , et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007; 17 (12) 1057-1064
    CrossrefPubMedGoogle Scholar
  • 18 Polakowska M, Kaleta D, Piotrowski W. , et al; On Behalf Of Wobasz Investigators; Multi-centre National Population Health Examination Survey (WOBASZ). Tobacco smoking in Poland in the years from 2003 to 2014. Pol Arch Intern Med 2017; 127 (02) 91-99
    PubMedGoogle Scholar
  • 19 Ueno M, Ferreiro JL, Desai B. , et al. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc Interv 2012; 5 (03) 293-300
    CrossrefPubMedGoogle Scholar
  • 20 Kunutsor SK, Spee JM, Kieneker LM. , et al. Self-reported smoking, urine cotinine, and risk of cardiovascular disease: findings from the PREVEND (prevention of renal and vascular end-stage disease) prospective cohort study. J Am Heart Assoc 2018; 7 (10) e008726
    PubMedGoogle Scholar
  • 21 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. ; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502
    CrossrefPubMedGoogle Scholar
  • 22 Bhatt DL, Fox KA, Hacke W. , et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354 (16) 1706-1717
    CrossrefPubMedGoogle Scholar
  • 23 Sibbing D, Bernlochner I, Kastrati A, Paré G, Eikelboom JW. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. Circ Cardiovasc Interv 2011; 4 (05) 505-513 , discussion 513
    CrossrefPubMedGoogle Scholar
  • 24 Brar SS, ten Berg J, Marcucci R. , et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58 (19) 1945-1954
    CrossrefPubMedGoogle Scholar
  • 25 Mangiacapra F, Patti G, Peace A. , et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 2010; 106 (05) 619-623
    CrossrefPubMedGoogle Scholar
  • 26 Geisler T, Zürn C, Simonenko R. , et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31 (01) 59-66
    CrossrefPubMedGoogle Scholar
  • 27 Reed GW, Cannon CP, Waalen J. , et al. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Catheter Cardiovasc Interv 2017; 89 (02) 190-198
    CrossrefPubMedGoogle Scholar